Molecular Exploitation of Apoptosis Pathways in Prostate Cancer

Natasha Kyprianou
University of Kentucky, USA
Contents

Preface vii

Chapter 1 Introduction: Prostate Cancer 1

Chapter 2 The Prostate Gland Dynamics 13

Chapter 3 Apoptosis Pathways Signaling Execution of Cancer Cells 21
  3.1 Cell Choices of Life and Death 21
    3.1.1 “Classic” apoptosis 24
    3.1.2 Anoikis 28
  3.2 Caspases: The Apoptosis Executioners in a Therapeutic Setting 28
  3.3 The Mitochondrion: A Convenient Cell-Killing Platform 32
  3.4 Cell Surface Death Receptors and the FAS Ligand 33
  3.5 Meet the BCL-2 Family: Governors of Cell Survival and Death 33
  3.6 The Transcriptional Controllers 36
  3.7 The p53 Tumor Suppressor 37
  3.8 PTEN/PI3K/AKT: The Downstream Intracellular Players 38
  3.9 The Antagonists of Death: Inhibitors of Apoptosis Proteins (IAPs) 40
  3.10 Apoptosis Signaling in the Endoplasmic Reticulum: A Death Platform for Stress 41
3.11 The Tumor Microenvironment: Extracellular Forces Control Intracellular Death Outcomes 43
  3.11.1 Role of hypoxia 44
  3.11.2 The key growth factors 44
  3.11.3 Inflammation 48

Chapter 4 Androgen Receptor-Mediated Apoptosis: Significance in Development of Castration-Resistant Prostate Cancer 53
  4.1 The Androgen Receptor (AR) 53
  4.2 Androgen Ablation: The Glory and the Failures 54
  4.3 AR Status in Castration-Resistant Prostate Cancer 56
  4.4 AR Interactions with Growth Factor Signaling Leads to Apoptosis 58
    4.4.1 AR connects with EGF 59
    4.4.2 AR and IGF interactions 61
    4.4.3 AR and TGF-β: partners in life and death (of the cell) 62
    4.4.4 AR and FGF interactions 67
    4.4.5 AR and VEGF: Vascular exchanges for the “road” 68
    4.4.6 AR and growth factor interplay in the stroma 69

Chapter 5 Anoikis in Prostate Cancer Metastasis 71
  5.1 Anoikis Interrupted: Survival of the Homeless (Cells) 71
  5.2 The Integrin Connection 73
  5.3 Impairing the Route to Angiogenesis 75
    5.3.1 Doxazosin 78
    5.3.2 Suramin 79
    5.3.3 Thalidomide 79
    5.3.4 Bevacizumab 80
    5.3.5 SU5416 80
  5.4 Anoikis and the Tumor Microenvironment: No “Resting” in the Stroma 80
  5.5 Signaling the “Homeless” State: Intracellular Anoikis Effectors 82
  5.6 Significance of Apoptosis in Cytoskeleton and Microtubule Targeting 88
  5.7 Autophagy: The Cellular Benefits of Starving to Death 91
Contents

Chapter 6  Epithelial-Mesenchymal Transition (EMT) in Prostate Cancer Metastasis 95

Chapter 7  Novel Molecular Therapeutics for Targeting Castration-Resistant Prostate Cancer 103
  7.1  Therapeutic Targeting of TGF-β Signaling 103
  7.2  Exploitation of Quinazolines: Lifting Anoikis Resistance to Impair Metastasis 107
  7.3  Receptor Tyrosine Kinase Targeting 109
  7.4  Histone Deacetylase Inhibitors (HDACs): Therapeutic Inhibitors 110
  7.5  Selective Death Action by Cancer-Specific PAR-4 in Prostate Tumors 112
  7.6  Death Synergy Between Proteosome and Death Receptor Leads to Tumor Regression 113
  7.7  The SERCA Pump as a Therapeutic Target 115
  7.8  Endothelin-Receptor Antagonists 117
  7.9  The Power of Sex Steroid Targeting 118

Chapter 8  Apoptotic-Based Molecular Markers of Therapeutic Response 121

Chapter 9  Role of Apoptosis in Prostate Cancer Prevention 125
  9.1  Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 127
  9.2  Statins 130
  9.3  Antioxidants 131
  9.4  5α-Reductase Inhibitors 134

Chapter 10  Summary and Future Directions 137

Bibliography 149

Abbreviations 211

Index 215

Acknowledgements 219